Faron, Priaxon enter collaboration to develop new AOC3/SSAO antagonists

Faron Pharmaceuticals Ltd., Turku, Finland and Priaxon AG, Munich, Germany today announced the entry into a collaboration and commercialization agreement to obtain new superior AOC3/SSAO antagonists. This collaboration combines two world-class technologies, the thorough understanding of the AOC3-protein and its ligand interaction with the rapid discovery engine for the development of new chemical inhibitors of protein-protein interactions. The goal of the collaboration is to create completely new scaffold structures to modify this interaction and the AOC3 function with orally available drugs.

“The collaboration with Priaxon will take us to the next stage of the development of new superior antagonists of the AOC3 protein and its ligand interaction”

"AOC3 and its enzymatic domain SSAO (semicarbazide-sensitive amine oxidase) have a central role in many chronic inflammatory conditions that could lead to deterioration of vasculature and key organs", said Dr. Markku Jalkanen, Chief Executive Officer of Faron Pharmaceuticals. "The collaboration with Priaxon will take us to the next stage of the development of new superior antagonists of the AOC3 protein and its ligand interaction".

"We are delighted to be working with Faron who we recognize as leaders in the biology of the AOC3 and its ligands," said Dr.Jürgen Kolb, Chief Executive Officer of Priaxon. "Our strength is to rapidly uncover small molecule therapeutics from our vast pre-encoded chemical reaction library and we are convinced that Priaxon is able to develop promising inhibitors of AOC3."